Showing results (221-230 of 976) with videos related to

Sort By:
Pageof 98
NPJ Breast Cancer|June 6, 2026
The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor statusKei Kawashima, Masanori Oshi, Akimitsu Yamada, et al.
NPJ Breast Cancer|June 5, 2026
Targeted axillary dissection in breast cancer patients: a systematic review and meta-analysisMohammed N Abdelaziz, Sagad O O Mohamed, Mohammed Hesham Nagi, et al.
NPJ Breast Cancer|August 5, 2023
Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical modelsLorna Hopcroft, Eleanor M Wigmore, Stuart C Williamson, et al.
NPJ Breast Cancer|July 14, 2023
Tumor-agnostic ctDNA levels by mFAST-SeqS in first-line HR-positive, HER2 negative metastatic breast cancer patients as a biomarker for survivalNoortje Verschoor, Vanja de Weerd, Mai N Van, et al.
NPJ Breast Cancer|June 21, 2023
Phase III study of HR-positive/HER2-negative/lymph node-positive breast cancer non-responsive to primary chemotherapy: a randomized trialYang Yang, Yingjian He, Zhaoqing Fan, et al.
NPJ Breast Cancer|June 13, 2023
Racial disparity in tumor microenvironment and distant recurrence in residual breast cancer after neoadjuvant chemotherapyGina Kim, Burcu Karadal-Ferrena, Jiyue Qin, et al.
NPJ Breast Cancer|May 5, 2026
Co-occurring rare germline DNA repair gene variants in BRCA1/BRCA2 implicated hereditary breast cancer familiesWejdan M Alenezi, Neil Recio, Caitlin T Fierheller, et al.
NPJ Breast Cancer|April 7, 2026
Progesterone receptors drive advanced breast cancer phenotypes including circulating tumor- and stem-like cell expansion in the context of ESR1 mutationThu H Truong, Noelle E Gillis, Amy R Dwyer, et al.
NPJ Breast Cancer|April 8, 2026
Biomarker, treatment patterns, and survival differences in metastatic triple-negative breast cancer by race in the United StatesPegah Farrokhi, Leah Park, Howard Weston Schmutz, et al.
NPJ Breast Cancer|April 8, 2026
Long-term prognostic value of ctDNA in early breast cancer: insights from the neoadjuvant ABCSG-34 TrialDaniel Egle, Dominik Hlauschek, Simon Peter Gampenrieder, et al.
Pageof 98